Home

John S Yu

CIK 1550545 · CEO and Chairman · last filed 2025-11-26

John S Yu is a CEO and Chairman who has filed 14 SEC Form 4 insider transactions across 3 companies since 2012. The most recent filing, for KAPA, was dated Nov 26, 2025. Across all open-market trades the lifetime net is −$865.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.46M

Companies

3

Total Filings

14

Lifetime Open-Market Net

-$865.4K

Filer Profile

Reported Address
21900 BURBANK BOULEVARD, 3RD FLOOR
WOODLAND HILLS, CA 91367
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KAPA CEO and Chairman 792,382 $1.85 $1.46M $5.8K 3 2025-11-26
ImmunoCellular Therapeutics, Ltd. (IMUC.WS) Delisted Director 120,508 — — $0 1 2018-06-08
ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Secretary 77 — — -$871.2K 10 2016-06-21

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-11-26 KAPA Grant (A) +190,840 $0 EDGAR
2025-02-24 KAPA Grant (A) +14,000 $0 EDGAR
2024-11-21 KAPA Buy (P) +4,000 $5.8K EDGAR
2018-06-08 ImmunoCellular Therapeutics, Ltd. (IMUC.WS) Delisted Grant (A) +120,000 $0 EDGAR
2016-06-21 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Grant (A) — $0 EDGAR
2015-10-01 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Mixed +10,326 -$0 EDGAR
2015-06-30 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Grant (A) — $0 EDGAR
2015-03-24 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Grant (A) — $0 EDGAR
2014-03-10 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Grant (A) — $0 EDGAR
2013-11-27 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Mixed — -$84.7K EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.